Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents

  • Yoshinari Enomoto
  • Raisuke Iijima
  • Masahide Tokue
  • Naoshi Ito
  • Yoshinori Nagashima
  • Tadashi Araki
  • Kenji Yamazaki
  • Makoto Utsunomiya
  • Masaki Hori
  • Hideki Itaya
  • Masanori Shiba
  • Hidehiko Hara
  • Masato Nakamura
  • Kaoru Sugi
Original Article

Abstract

In the era of drug-eluting stents (DES), a long-term dual antiplatelet therapy is required to prevent late stent thrombosis. However, in patients with atrial fibrillation (AF), there is a concern that combining warfarin with dual antiplatelet therapy may increase the risk of bleeding. We analyzed 1274 consecutive patients with coronary artery disease who were treated with coronary intervention from January 2006 through January 2009. Of these, we enrolled 74 AF patients treated with DES and dual antiplatelet therapy as well as warfarin. The primary endpoint was the incidence of major bleeding within 3 years; the predictive factor of major bleeding was also analyzed. To evaluate the efficacy of anticoagulant therapy, time in therapeutic range (TTR) was also measured. The 3-year incidence of major bleeding was 12.2 % (nine of 74 patients). The average observation period was 25.7 ± 20.2 months. Mean TTR value was 44.6 ± 33.0 % and was maintained at a relatively low level. Multivariate analysis revealed that a higher CHADS2 score (2-point more) was an independent predictor of increased risk of major bleeding. Major bleeding in the patients with triple antithrombotic therapy including warfarin occurred at a relatively high rate. Although the higher CHADS2-score indicates a high risk of thrombotic events, it was strongly associated with bleeding complications.

Keywords

Drug-eluting stent Triple antithrombotic therapy Time in the therapeutic range CHADS2 score 

References

  1. 1.
    Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Mauri L, Hsieh WH, Massaro JM, Ho KKL, D’Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007;49:734–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.PubMedCrossRefGoogle Scholar
  5. 5.
    Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007;6:981–93.PubMedCrossRefGoogle Scholar
  6. 6.
    Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–40.PubMedCrossRefGoogle Scholar
  8. 8.
    Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H, J-RHYTHM Registry Investigators. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ J. 2011;75:1328–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236–9.PubMedGoogle Scholar
  10. 10.
    Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, ACTIVE W Investigators, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029–37.PubMedCrossRefGoogle Scholar
  11. 11.
    Takasawa Y, Iijima R, Shiba M, Nakamura M, Sugi K. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention. J Cardiol. 2010;55:391–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, REPLACE-2 Investigators, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.PubMedCrossRefGoogle Scholar
  14. 14.
    Fauchier L, Pellegrin C, Bernard A, Clementy N, Angoulvant D, Lip GY, et al. Comparison of frequency of major adverse events in patients with atrial fibrillation receiving bare-metal versus drug-eluting stents in their coronary arteries. Am J Cardiol. 2012;110:7–12.PubMedCrossRefGoogle Scholar
  15. 15.
    Iijima R, Ndrepepa G, Mehilli J, Byrne RA, Schulz S, Neumann FJ, et al. Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. Eur Heart J. 2009;30:290–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Porter A, Konstantino Y, Iakobishvili Z, Shachar L, Battler A, Hasdai D. Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006;68:56–61.PubMedCrossRefGoogle Scholar
  17. 17.
    Khurram Z, Chou E, Minutello R, Bergman G, Parikh M, Naidu S, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol. 2006;18:162–4.PubMedGoogle Scholar
  18. 18.
    Karjalainen PP, Porela P, Ylitalo A, Vikman S, Nyman K, Vaittinen MA, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007;28:726–32.PubMedCrossRefGoogle Scholar
  19. 19.
    Ruiz-Nodar JM, Marín F, Hurtado JA, Valencia J, Pinar E, Pineda J, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008;51:818–25.PubMedCrossRefGoogle Scholar
  20. 20.
    Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107–15.PubMedCrossRefGoogle Scholar
  21. 21.
    You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e531S–75S.PubMedCentralPubMedGoogle Scholar
  22. 22.
    Schulz S, Schuster T, Mehilli J, Byrne RA, Ellert J, Massberg S, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009;30:2714–21.PubMedCrossRefGoogle Scholar
  23. 23.
    Kimura T, Morimoto T, Nakagawa Y, Kadota K, Nozaki Y, Tada T, et al. Antiplatelet therapy and long-term clinical outcome after sirolimus-eluting stent implantation: 5-year outcome of the j-Cypher registry. Cardiovasc Interv Ther. 2012;27:181–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Byrne RA, Schulz S, Mehilli J, Iijima R, Massberg S, Neumann FJ, Intracoronary Stenting and Antithrombotic Regimen: Safety and EFficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Investigators, et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J. 2009;157:620–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125:2015–26.PubMedCrossRefGoogle Scholar
  26. 26.
    NIPPON trial; Nobori Dual Antiplatelet Therapy as Appropriate Duration. http://clinicaltrials.gov/ct2/show/NCT01514227?term=nippon+trial&rank=1. Accessed 10 Oct 2012.

Copyright information

© Japanese Association of Cardiovascular Intervention and Therapeutics 2013

Authors and Affiliations

  • Yoshinari Enomoto
    • 1
  • Raisuke Iijima
    • 1
  • Masahide Tokue
    • 1
  • Naoshi Ito
    • 1
  • Yoshinori Nagashima
    • 1
  • Tadashi Araki
    • 1
  • Kenji Yamazaki
    • 1
  • Makoto Utsunomiya
    • 1
  • Masaki Hori
    • 1
  • Hideki Itaya
    • 1
  • Masanori Shiba
    • 1
  • Hidehiko Hara
    • 1
  • Masato Nakamura
    • 1
  • Kaoru Sugi
    • 1
  1. 1.Division of Cardiovascular Medicine, Ohashi HospitalToho University Medical CenterTokyoJapan

Personalised recommendations